Clinical trial
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related…
NCT00020449 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020449 |
|---|---|
| Title | Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma |
| Official title | A Phase II Study of Liposomal Doxorubicin and Interleukin-12 in AIDS-Associated Kaposi's Sarcoma Followed by Chronic Administration of Interleukin-12 |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological, Drug |
| Interventions | recombinant interleukin-12, paclitaxel, pegylated liposomal doxorubicin hydrochloride |
| Start date | Jan 1, 2001 |
| Completion | May 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: